New fast test to diagnose bacterial endophthalmitis

Article

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

A newly-developed fast real-t PCR (f-real-t PCR) test is an effective and much more rapid way to diagnose bacterial endophthalmitis (BE), concluded a study published online ahead of print by the British Journal of Ophthalmology.

Pablo Goldschmidt, of the Laboratoire du Centre National d’Ophtalmologie des Quinze-Vingts, France, and colleagues examined specimens of vitreous fluid (VF) and aqueous humour (AH) cells from endophthalmitis, infected with bacteria or non-infective disorders and control to determine if the f-real-t PCR testing method they had developed could overcome the barriers most commonly associated with BE testing, including insufficient VF or AH, PCR cross-contamination and culture insensitivity, to identify the bacteria and Genera of the DNA that had been extracted from the specimen cells. The team compared the diagnoses with those from direct microscopic examination and culture.

The f-real-t PCR showed no cross-reactivity with fungi even though it detected ≥0.01 CFU Bac/µl and had a 100% correlation with culture positive results. Of the BE samples, 60% tested culture positive; with f-real-t PCR, this was 90%. Within 90 minutes, the f-real-t PCR detected and quantified the presence of Bac, Staphylococci, Streptococci, Haemophilus, Pseudomonas, Enterobacteria, Acinetobacter, Propionbacteriacae and Corynebacteria. The non-infective cells tested negative.

The team therefore concluded that their f-real-t PCR test reduced substantially the hours or even days required for cultures, and provided a more accurate result. The test’s developers now plan to run a larger series of samples to assess the utility of the test.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Related Content
© 2024 MJH Life Sciences

All rights reserved.